In March 2016 Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Padlock to continue the development of medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complex formation in autoimmune diseases.
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal
Padlock Therapeutics – FierceBiotech’s 2015 Fierce 15
Atlas’ Padlock scoops up some GlaxoSmithKline assets in autoimmunity
Padlock Banks $23M with a Fresh Approach to Autoimmune Disease
Déjà Vu For Gilman as New Immunology Startup, Padlock, Gets $23M
Rekindling the Flame
Location: United States, Massachusetts, Cambridge
Total raised: $23M
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 18.12.2014 | Series A | $23M | - | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 18.12.2014 | Padlock Th... | Padlock Therapeutics, a Cambri... | USA | - | finsmes.co... |
| 18.12.2014 | Padlock Th... | CAMBRIDGE, MA, Biotechnology... | - | - | vcnewsdail... |